Viewing nowCombinationOlmeduo Tablet 5/40 Milligrams
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 201404595 · Approved 2014.10.06 · Insurance code 670607100
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower and manage the blood pressure of patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil.
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
∘Pediatric patients: The safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication may cause severe harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to the active or related ingredients, during pregnancy or lactation, in patients with severe liver disease or specific heart conditions, in patients undergoing kidney dialysis, in patients in shock, or in certain diabetes patients. Hypotensive patients with fluid or salt depletion may experience initial hypotensive symptoms upon starting this medication, so their condition should be closely monitored, and patients with severe heart conditions should be particularly cautious as sudden vasodilation may result in hypotension. Patients with heart failure or poor kidney function should use this medication carefully, as it may worsen kidney function. This medication can cause various side effects, including dizziness, headache, hypotension, nausea, rash, and swelling; rare severe allergic reactions or liver function abnormalities may also occur. Use during pregnancy should be avoided due to the risk of fetal damage, and lactating women should either discontinue breastfeeding or the medication, as adverse reactions may occur in infants. Safety and efficacy have not been established in children under 18 years of age, so it is not recommended. Elderly patients may have decreased kidney and liver function, so starting at a low dose and closely monitoring their condition is advised. In cases of overdose, severe hypotension and symptoms due to vasodilation may occur, and immediate medical treatment should be sought. This medication should be stored in a tightly sealed container, away from moisture, heat, and direct sunlight, and should not be transferred to another container. Additionally, this medication may interact with other drugs, so it is essential to consult a healthcare professional if taking other medications.
This medication should be stored in a sealed container to protect it from exposure to air and moisture, preferably at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness for a longer period.
Light yellow round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.